Overview

An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta

Status:
Withdrawn
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the effect of BPS804 on strength/quality of bone in patients with Type I, III or IV Osteogenesis imperfecta using a special type of CT scanner. Participants will be treated for 1 year.
Phase:
Phase 2
Details
Lead Sponsor:
Mereo BioPharma
Collaborator:
ICON Clinical Research